Therapeutic approaches utilizing OPN small interfering RNA and anti-OPN neutralizing antibodies have been employed in cancer and inflammatory diseases [46–50] and have demonstrated the potential importance of OPN regulation as a therapeutic target. The gene discussed is SPP1; the disease is cancer.